Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

KRT8 Antibodies

Cytokeratin 8 (CK8) is a protein encoded by the KRT8 gene on chromosome 12q13.13 in humans. It typically consists of approximately 483 amino acids and has a molecular weight of around 53 kDa. Post-translational modifications of CK8 include phosphorylation, glycosylation, and the formation of disulfide bonds, which contribute to its structural stability and functional diversity. CK8 is primarily an intracellular protein, forming intermediate filaments that provide structural support and integrity to epithelial cells. This protein is a key component of the cytoskeleton, contributing to the mechanical strength and stability of epithelial cells. Additionally, CK8 is involved in various cellular processes, including cell signaling, migration, and apoptosis.

CK8 is expressed in various organs, tissues, and cell types, with particularly high levels observed in simple epithelia lining ducts and tubules. It is abundantly expressed in organs such as the liver, pancreas, kidney, and gastrointestinal tract. Various factors, including developmental cues, hormonal signals, and tissue-specific transcription factors, regulate the expression of CK8. Aberrant CK8 expression patterns have been observed in various cancers, including hepatocellular carcinoma, pancreatic cancer, and breast cancer. In clinical practice, CK8 expression patterns aid in determining the tissue origin of tumors, particularly in metastatic cancers, and contribute to accurate diagnosis and treatment planning. Furthermore, CK8 expression provides valuable prognostic information, with associations observed between CK8 expression and tumor subtype, aggressiveness, and patient outcomes in cancers such as breast, pancreatic, and hepatocellular carcinoma. Additionally, CK8 expression plays a role in distinguishing between different types of liver lesions in liver diseases. CK8 is an important biomarker that guides treatment decisions, predicts patient outcomes, and improves overall patient care in oncology and clinical pathology.

NeoBiotechnologies offers a variety of antibodies against CK8 that have been validated for flow cytometry, immunofluorescence, immunohistochemistry, and Western blotting. Additionally, we hold exclusive rights to CK8 antibodies available for licensing or collaboration [https://www.neobiotechnologies.com/shop/?s=KRT8].


Keratin, type II cytoskeletal 8, Cytokeratin-8, Keratin-8, Type-II keratin Kb8, CARD2; CK8; CYK8; CYKER; Cytokeratin Endo A; DreK8; K2C8; K8; Keratin 8; Krt 2.8; KRT8; Type-II Keratin Kb8. Cell Proliferation-inducing Gene 46 Protein; CK18; CYK18 Cytokeratin Endo B; K18; Keratin-18; Kerd; KRT18, KRT8/18, CK8/18

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lung Cancer, MAPK Signaling, Mast Cell Marker, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors

Showing 1–25 of 31 results


Showing 1–25 of 31 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.